| Acute Respiratory Distress Syndrome |
1 |
0.28 |
| Child |
0 |
0.85 |
| Glucocorticoid |
0 |
0.64 |
| Hospital |
0 |
0.27 |
| Biologic Therapy |
0 |
0.2 |
| COVID-19 |
0 |
0.2 |
| Clinical Research |
0 |
0.16 |
| Steroids |
0 |
0.16 |
| Social Determinants of Health |
0 |
0.14 |
| Health Care Quality, Access, and Evaluation |
0 |
0.11 |
| Texas |
0 |
0.11 |
| Washington |
0 |
0.11 |
| Intravenous Immunoglobulin (IVIG) |
0 |
0.09 |
| Corticosteroids |
0 |
0.05 |
| Europe |
0 |
0.05 |
| Fellowship |
0 |
0.05 |
| Fever |
0 |
0.05 |
| Immunocompromise |
0 |
0.05 |
| Immunoglobulin A (IgA) |
0 |
0.05 |
| Intravenous |
0 |
0.05 |
| Match |
0 |
0.05 |
| Severe Acute Respiratory Syndrome (SARS) |
0 |
0.05 |
| Shock |
0 |
0.05 |
| Stress |
0 |
0.05 |